Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Immunocore Holdings (IMCR) EBITDA (2023 - 2025)

Immunocore Holdings' EBITDA history spans 3 years, with the latest figure at -$28.1 million for Q4 2025.

  • For Q4 2025, EBITDA fell 6.74% year-over-year to -$28.1 million; the TTM value through Dec 2025 reached -$29.8 million, up 38.6%, while the annual FY2025 figure was -$29.8 million, 38.6% up from the prior year.
  • EBITDA for Q4 2025 was -$28.1 million at Immunocore Holdings, down from -$3.6 million in the prior quarter.
  • Across five years, EBITDA topped out at $12.0 million in Q3 2024 and bottomed at -$28.1 million in Q4 2025.
  • The 3-year median for EBITDA is -$10.5 million (2023), against an average of -$9.6 million.
  • The largest YoY upside for EBITDA was 185.32% in 2024 against a maximum downside of 4508.57% in 2024.
  • A 3-year view of EBITDA shows it stood at -$572000.0 in 2023, then crashed by 4508.57% to -$26.4 million in 2024, then dropped by 6.74% to -$28.1 million in 2025.
  • Per Business Quant, the three most recent readings for IMCR's EBITDA are -$28.1 million (Q4 2025), -$3.6 million (Q3 2025), and -$3.8 million (Q2 2025).